MBX
MBX Biosciences·NASDAQ
--
--(--)
--
--(--)
5.61 / 10
Netural
Fund flow analysis scores 7.82/10, reflecting robust bullish liquidity across block, small, medium, large, and extra-large transactions. Analyst sentiment is cautiously optimistic, with two active analysts (Guggenheim: Strong Buy; Barclays: Buy) and a historical weighted rating of 3.40. Despite a recent price decline (-9.08%), the consensus expectation is neutral to slightly positive.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-28
InstitutionBarclays
Times predicted1
Historical Win Rate100.0%
What is the analyst consensus for MBX?
- MBX holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.61/10 (Netural).
